Recommended Changes for Pharma Companies in Response to COVID-19

[Fill out the form below to register]

PhUSE: Retrospective vs. Proactive Anonymization of Narratives mms holdings cro ema policy 0070 clinical trial transparency

In the wake of the COVID-19 pandemic, governments across the globe have rushed to implement countermeasures and develop best practices to curtail the spread of the virus, impacting the conduct of clinical trials in unprecedented ways.  As a result, regulatory authorities quickly developed and continue to refine guidance on conducting clinical research in this very challenging environment.

In this complementary webinar, MMS regulatory experts discuss changes pharmaceutical companies should consider implementing in response to COVID-19. They focus not only on  changes to study-related documents recommended by regulatory authorities, but other aspects affecting trials, including:

  • the potential need for increased pharmacovigilance,
  • how to provide for and manage additional study vendors,
  • the potential for remote auditing,
  • preparing for additional requirements in personnel training, and
  • what all of these changes mean to regulatory strategy.

Attendees will learn how to move clinical trials forward during the pandemic while ensuring complete regulatory compliance.

Presenters:

Barbara A. Rusin, Senior Regulatory Compliance Manager, MMS

Ben Kaspar, Global Regulatory Affairs Manager, MMS

Register for the webinar

Suggested For You

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

perspectives

November 12th, 2024

REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders